Latest news with #XTANDI
Cision Canada
14 hours ago
- Business
- Cision Canada
XTANDI® (enzalutamide) now funded in Ontario for all approved prostate cancer indications Français
XTANDI is the first and only androgen receptor pathway inhibitor (ARPI) indicated and reimbursed in Ontario for use in patients with nmCSPC with biochemical recurrence at high risk for metastasis MARKHAM, ON, June 26, 2025 /CNW/ - Today, Astellas Pharma Canada, Inc. announced that XTANDI ® (enzalutamide) is now funded by the Ontario Drug Benefit Program under the Exceptional Access Program for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence (BCR) at high risk of metastasis (high-risk BCR). i This decision means XTANDI is now publicly reimbursed in Ontario for all of its approved prostate cancer indications. Health Canada granted Astellas market authorization for XTANDI in nmCSPC in January 2024. This approval was expedited as a result of XTANDI's inclusion in Project Orbis, an initiative of regulatory bodies, including Health Canada, with an aim to give patients faster access to promising cancer treatments in some countries around the world. The swift decision to reimburse XTANDI in Ontario is an important milestone towards making this important therapy available to Ontarians. "The public reimbursement of XTANDI in Ontario is important because it expands access to a vital treatment for prostate cancer patients who are at high risk of metastasis," said Tony Finelli, MD, FRCSC, Professor of Surgery and Chair of Urology, University of Toronto, Urologic Oncologist, University Health Network (UHN). "Reducing the barriers to accessing XTANDI allows us as physicians to offer even more comprehensive care to those navigating the challenges of living with prostate cancer." "We applaud Ontario's decision to publicly reimburse XTANDI for the treatment of nmCSPC patients with high-risk BCR," said Sandra Heller, General Manager, Astellas Pharma Canada. "At Astellas, we remain dedicated to ensuring that patients have access to the therapies they require for better health outcomes, and we are honoured to support men facing this difficult journey." Reimbursement Criteria Specific reimbursement criteria must be met for public coverage of XTANDI. Complete information can be found by consulting the Ontario Drug Benefit Program under the Exceptional Access Program for details. About nmCSPC Prostate cancer develops when abnormal cells form and grow in the prostate gland. ii nmCSPC describes the early stage of prostate cancer wherein the disease remains localized and still responds to medical or surgical treatment to lower testosterone levels. iii Of men who have undergone definitive prostate cancer treatment, including radical prostatectomy, radiotherapy, or both, an estimated 20-40 per cent will experience a biochemical recurrence (BCR) within 10 years. iv About 9 out of 10 men with high-risk BCR will develop metastatic disease, and 1 in 3 will die as a result of their metastatic prostate cancer. v As the most common cancer among Canadian men, prostate cancer accounts for an average of 76 new diagnosis every day. vi It is estimated that about 1 in 8 Canadian men will develop prostate cancer during their lifetime and 1 in 30 will die from it. vii Approximately 98 per cent of cases occur in men above the age of 50. viii About XTANDI (enzalutamide) XTANDI is an androgen receptor (AR) inhibitor that overcomes resistance to conventional antiandrogens by inhibiting AR signaling at multiple steps in the pathway. ix XTANDI is approved for use in men in four prostate cancer disease states across five indications: The treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR). The treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). The treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients: chemotherapy-naïve and post-docetaxel Please consult the Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The product monograph is also available by calling Astellas Medical Information at 1-888-338-1824. XTANDI is a standard of care that has received regulatory approvals in more than 90 countries, including the United States, the European Union and Japan. About XTANDI Patient Assistance Program Astellas is committed to supporting patients prescribed XTANDI through the XTANDI Patient Assistance Program by offering coverage navigation, financial assistance, patient and caregiver education as well as specialty pharmacy dispensing. Patients with a valid prescription can be enrolled by calling 1-855-982-6348. About Astellas Pharma Canada Astellas Pharma Canada, Inc. is a Canadian affiliate of Tokyo-based Astellas Pharma Inc., a global life sciences company conducting business in more than 70 countries around the world. Astellas is committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at SOURCE Astellas Pharma Canada, Inc.
Yahoo
24-05-2025
- Business
- Yahoo
Pfizer Inc. (PFE) Delivers Oncology Milestones with MesoC2 Debut and XTANDI Survival Boost
Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust five-year survival results for XTANDI (enzalutamide) combined with androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer. Data from the Phase 3 ARCHES trial show XTANDI plus ADT cuts the risk of death by 30%, with a 66% five-year survival rate versus 53% for ADT alone. XTANDI is now the first androgen receptor inhibitor to demonstrate such a long-term survival benefit, reinforcing its position as a standard of care for this patient group. Pixabay/Public Domain Despite these clinical milestones and ongoing innovation, including first-in-human studies of new oncology drugs, Pfizer Inc. (NYSE:PFE)'s shares rose just 2%, in line with broader market resilience amid renewed trade tensions. Over the past year, PFE's total return, factoring in dividends, is down 14.32%, lagging the overall US pharmaceuticals sector. Analysts see upside potential, with a consensus price target of $29.50, but note that future performance hinges on continued drug approvals, successful market expansion, and operational efficiency. Pfizer Inc. (NYSE:PFE)'s strategic collaborations and licensing agreements remain key as the company navigates competitive pressures and shifting revenue streams. While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Pfizer (NYSE:PFE) Showcases New Cancer Treatment Study And Reports Prostate Cancer Drug Success
Pfizer recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and announced five-year beneficial survival results for XTANDI combined with ADT therapy. Despite these significant developments, the company's shares rose 2%, in line with broader market movements which showed resilience despite trade tensions revived by President Trump's tariff threats. Given the market's overall downward trend, Pfizer's performance reflects stability within the pharmaceuticals sector, buoyed by its ongoing advancements and strategic collaborations, including recent partnerships and licensing agreements. We've identified 3 weaknesses for Pfizer that you should be aware of. We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Pfizer's recent announcements on cancer research advancements and significant survival results for XTANDI, while contributing positively to short-term share price movement, present a mixed impact on the company's financial outlook. Despite promising developments on the oncology front, Pfizer shares have seen a total return of 14.32% decline over the past year when including both share price and dividends, which places its performance behind that of the US Pharmaceuticals industry over the same period. The company's revenue and earnings forecasts are influenced by these announcements. Advancements in drug development can potentially boost revenue streams, yet increased competition and declining sales from key products pose substantial challenges. Market expectations may already account for some of these pressures, as reflected in the current trading dynamics. At present, the analyst consensus gives Pfizer a fair value price target of US$29.50, with the company's current share price sitting at a discount compared to this target, suggesting some upside potential assuming positive catalysts play out effectively. Going forward, maintaining or surpassing this forecast depends heavily on the sustained success of new drug approvals and market expansion efforts, while managing expenses and operational efficiencies. Understand Pfizer's earnings outlook by examining our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Pfizer (NYSE:PFE) Showcases New Cancer Treatment Study And Reports Prostate Cancer Drug Success
Pfizer recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and announced five-year beneficial survival results for XTANDI combined with ADT therapy. Despite these significant developments, the company's shares rose 2%, in line with broader market movements which showed resilience despite trade tensions revived by President Trump's tariff threats. Given the market's overall downward trend, Pfizer's performance reflects stability within the pharmaceuticals sector, buoyed by its ongoing advancements and strategic collaborations, including recent partnerships and licensing agreements. We've identified 3 weaknesses for Pfizer that you should be aware of. We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Pfizer's recent announcements on cancer research advancements and significant survival results for XTANDI, while contributing positively to short-term share price movement, present a mixed impact on the company's financial outlook. Despite promising developments on the oncology front, Pfizer shares have seen a total return of 14.32% decline over the past year when including both share price and dividends, which places its performance behind that of the US Pharmaceuticals industry over the same period. The company's revenue and earnings forecasts are influenced by these announcements. Advancements in drug development can potentially boost revenue streams, yet increased competition and declining sales from key products pose substantial challenges. Market expectations may already account for some of these pressures, as reflected in the current trading dynamics. At present, the analyst consensus gives Pfizer a fair value price target of US$29.50, with the company's current share price sitting at a discount compared to this target, suggesting some upside potential assuming positive catalysts play out effectively. Going forward, maintaining or surpassing this forecast depends heavily on the sustained success of new drug approvals and market expansion efforts, while managing expenses and operational efficiencies. Understand Pfizer's earnings outlook by examining our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Pfizer (NYSE:PFE) Showcases New Cancer Treatment Study And Reports Prostate Cancer Drug Success
Pfizer recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and announced five-year beneficial survival results for XTANDI combined with ADT therapy. Despite these significant developments, the company's shares rose 2%, in line with broader market movements which showed resilience despite trade tensions revived by President Trump's tariff threats. Given the market's overall downward trend, Pfizer's performance reflects stability within the pharmaceuticals sector, buoyed by its ongoing advancements and strategic collaborations, including recent partnerships and licensing agreements. We've identified 3 weaknesses for Pfizer that you should be aware of. We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Pfizer's recent announcements on cancer research advancements and significant survival results for XTANDI, while contributing positively to short-term share price movement, present a mixed impact on the company's financial outlook. Despite promising developments on the oncology front, Pfizer shares have seen a total return of 14.32% decline over the past year when including both share price and dividends, which places its performance behind that of the US Pharmaceuticals industry over the same period. The company's revenue and earnings forecasts are influenced by these announcements. Advancements in drug development can potentially boost revenue streams, yet increased competition and declining sales from key products pose substantial challenges. Market expectations may already account for some of these pressures, as reflected in the current trading dynamics. At present, the analyst consensus gives Pfizer a fair value price target of US$29.50, with the company's current share price sitting at a discount compared to this target, suggesting some upside potential assuming positive catalysts play out effectively. Going forward, maintaining or surpassing this forecast depends heavily on the sustained success of new drug approvals and market expansion efforts, while managing expenses and operational efficiencies. Understand Pfizer's earnings outlook by examining our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
